BR112022018319A2 - Heteromultímeros actriia e actriib de braço único e métodos para tratar doenças ou condições renais - Google Patents

Heteromultímeros actriia e actriib de braço único e métodos para tratar doenças ou condições renais

Info

Publication number
BR112022018319A2
BR112022018319A2 BR112022018319A BR112022018319A BR112022018319A2 BR 112022018319 A2 BR112022018319 A2 BR 112022018319A2 BR 112022018319 A BR112022018319 A BR 112022018319A BR 112022018319 A BR112022018319 A BR 112022018319A BR 112022018319 A2 BR112022018319 A2 BR 112022018319A2
Authority
BR
Brazil
Prior art keywords
arm
heteromultimers
actriia
conditions
methods
Prior art date
Application number
BR112022018319A
Other languages
English (en)
Inventor
Li Gang
Kumar Ravindra
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of BR112022018319A2 publication Critical patent/BR112022018319A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

HETEROMULTÍMEROS ACTRIIA E ACTRIIB DE BRAÇO ÚNICO E MÉTODOS PARA TRATAR DOENÇAS OU CONDIÇÕES RENAIS. Em alguns aspectos, a revelação se refere a heteromultímeros de ActRIIA de braço único e heteromultímeros ActRIIB de braço único e métodos de uso de tais heteromultímeros para tratar, prevenir ou reduzir a taxa de progressão e/ou gravidade de doenças ou condições renais, particularmente tratar, prevenir ou reduzir a taxa de progressão e/ou gravidade de uma ou mais complicações de associação renal. A revelação também fornece métodos de uso de um heteromultímero de ActRIIA de braço único ou heteromultímero ActRIIB de braço único para tratar, prevenir ou reduzir a taxa de progressão e/ou gravidade de uma variedade de condições incluindo, mas sem limitação a, síndrome de Alport, glomeruloesclerose segmentar focal (FSGS), doença renal policística e/ou doença renal crônica.
BR112022018319A 2020-03-13 2021-03-11 Heteromultímeros actriia e actriib de braço único e métodos para tratar doenças ou condições renais BR112022018319A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989037P 2020-03-13 2020-03-13
PCT/US2021/021991 WO2021183819A1 (en) 2020-03-13 2021-03-11 Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions

Publications (1)

Publication Number Publication Date
BR112022018319A2 true BR112022018319A2 (pt) 2022-11-22

Family

ID=77672098

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018319A BR112022018319A2 (pt) 2020-03-13 2021-03-11 Heteromultímeros actriia e actriib de braço único e métodos para tratar doenças ou condições renais

Country Status (10)

Country Link
US (1) US20230134083A1 (pt)
EP (1) EP4117707A4 (pt)
JP (1) JP2023528117A (pt)
KR (1) KR20230002391A (pt)
CN (1) CN115515618A (pt)
AU (1) AU2021236249A1 (pt)
BR (1) BR112022018319A2 (pt)
CA (1) CA3171638A1 (pt)
MX (1) MX2022011364A (pt)
WO (1) WO2021183819A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117137924A (zh) * 2023-09-28 2023-12-01 宜兴食品与生物技术研究院有限公司 N-乙酰-d-甘露糖胺在制备促进骨生长的食品及药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170141215A (ko) * 2015-04-06 2017-12-22 악셀레론 파마 인코포레이티드 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
MA54328A (fr) * 2015-04-06 2021-10-06 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41919A (fr) * 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CA3039074A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Compositions and method for treating kidney disease
JP7219705B2 (ja) * 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用

Also Published As

Publication number Publication date
JP2023528117A (ja) 2023-07-04
EP4117707A4 (en) 2024-08-07
US20230134083A1 (en) 2023-05-04
KR20230002391A (ko) 2023-01-05
WO2021183819A1 (en) 2021-09-16
EP4117707A1 (en) 2023-01-18
CA3171638A1 (en) 2021-09-16
CN115515618A (zh) 2022-12-23
AU2021236249A1 (en) 2022-10-06
MX2022011364A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
BR112018074028A2 (pt) composição detergente e método para tratar um substrato
CL2020002677A1 (es) Receptores quiméricos y metodos de uso de los mismos(divisional de solicitud 2310-2019)
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
BR112022018319A2 (pt) Heteromultímeros actriia e actriib de braço único e métodos para tratar doenças ou condições renais
EP3904681A3 (en) Active hydraulic ripple cancelation methods and systems
UY38182A (es) Receptores quiméricos de dll3 y métodos para su uso
MY181072A (en) Holding table
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
MY183043A (en) Laser lift-off method of wafer
EA201491816A1 (ru) Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
FR3031108B1 (fr) Composition comprenant un polymere a phases multiples, son procede de preparation et son utlisation
BR112017019942A2 (pt) composição líquida para lavagem de roupas e uso de polímero para a liberação de sujeira
WO2017023950A3 (en) Controlled fluid flow for cleaning an optical element
EA201891405A1 (ru) Стеклянная подложка для химического упрочнения и способ химического упрочнения с контролируемой кривизной
FR3029525B1 (fr) Poly(itaconate) reticule biosource, compositions l'incluant et utilisations comme polymere super absorbant
MX2019012256A (es) Almidones pregelatinizados que tienen una alta tolerancia al proceso y metodos para fabricar y usar los mismos.
EA201992086A1 (ru) Дренажный блок и промежуточная панель
BR112021023198A2 (pt) Antagonistas do sistema de complemento para uso em métodos de tratamento de neuropatias paraproteinêmicas
WO2023022968A3 (en) Compositions and methods for treating renal diseases or conditions
MX2018009628A (es) Sistema para limpiar una superficie de vidrio de un vehiculo.
FR3028861B1 (fr) Polymere obtenu par multi-etapes, sa composition, son procede de preparation, son utilisation et composition comprenant celui-ci
EA201391605A1 (ru) Способы очистки вирусов с использованием гельпроникающей хроматографии
GEP20247598B (en) Method for obtaining low-molecular-weight heparins by means of tangential flow filtration
MA53545A (fr) Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
RU2019124984A (ru) Среднемолекулярный гепарин

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]